SE0302361D0 - Inhibering av upptagning av monoamin - Google Patents

Inhibering av upptagning av monoamin

Info

Publication number: SE0302361D0
Authority: SE; Sweden
Prior art keywords: inhibition; monoamine; uptake; mammals; methods
Prior art date: 2001-03-06

Application number

SE0302361A

Other languages

English (en)

Other versions

SE526598C2 (sv

SE0302361L (sv

Inventor

David Taiwai Wong

Edward Louis Mattiuz

John-Michael Sauer

William Joe Wheeler

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-06

Filing date

2003-09-03

Publication date

2003-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23045157&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE0302361(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2003-09-03 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2003-09-03 Publication of SE0302361L publication Critical patent/SE0302361L/sv

2003-09-03 Publication of SE0302361D0 publication Critical patent/SE0302361D0/sv

2005-10-18 Publication of SE526598C2 publication Critical patent/SE526598C2/sv

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/48—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Pulmonology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Hematology (AREA)
Anesthesiology (AREA)
Diabetes (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

SE0302361A 2001-03-06 2003-09-03 R-(-)-N-metyl-3-((2-metyl-4hydroxifenyl)oxi)-3-fenyl-1-aminpropan samt farmaceutiska beredningar innefattande denna substans eller dess salt för inhibering av upptag av monoamin SE526598C2 (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27373001P	2001-03-06	2001-03-06
PCT/US2002/003385 WO2002070457A1 (en)	2001-03-06	2002-02-20	Inhibitor of monoamine uptake

Publications (3)

Publication Number	Publication Date
SE0302361L SE0302361L (sv)	2003-09-03
SE0302361D0 true SE0302361D0 (sv)	2003-09-03
SE526598C2 SE526598C2 (sv)	2005-10-18

Family

ID=23045157

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE0302361A SE526598C2 (sv)	2001-03-06	2003-09-03	R-(-)-N-metyl-3-((2-metyl-4hydroxifenyl)oxi)-3-fenyl-1-aminpropan samt farmaceutiska beredningar innefattande denna substans eller dess salt för inhibering av upptag av monoamin

Country Status (35)

Country	Link
US (2)	US20040082666A1 (sv)
EP (1)	EP1379492B1 (sv)
JP (1)	JP2004525912A (sv)
KR (1)	KR20030092012A (sv)
CN (1)	CN1229331C (sv)
AP (1)	AP2003002855A0 (sv)
AT (2)	AT414238B (sv)
AU (1)	AU2002245385B2 (sv)
BR (1)	BR0207716A (sv)
CA (1)	CA2440161A1 (sv)
CH (1)	CH695982A5 (sv)
CZ (1)	CZ20032380A3 (sv)
DE (1)	DE60226715D1 (sv)
DK (1)	DK200301267A (sv)
EA (1)	EA005768B1 (sv)
EC (1)	ECSP034760A (sv)
EE (1)	EE200300419A (sv)
ES (2)	ES2305221T3 (sv)
FI (1)	FI20031191L (sv)
GB (1)	GB2389851B (sv)
HR (1)	HRP20030710A2 (sv)
HU (1)	HUP0303341A3 (sv)
IL (1)	IL157779A0 (sv)
LT (1)	LT5143B (sv)
LU (1)	LU91038B1 (sv)
LV (1)	LV13119B (sv)
NO (1)	NO20033921L (sv)
NZ (1)	NZ527431A (sv)
OA (1)	OA12494A (sv)
PL (1)	PL363840A1 (sv)
SE (1)	SE526598C2 (sv)
SK (1)	SK10632003A3 (sv)
TR (1)	TR200705146T1 (sv)
WO (1)	WO2002070457A1 (sv)
ZA (1)	ZA200306882B (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU91038B1 (fr) *	2001-03-06	2003-09-11	Lilly Co Eli	Inhibiteur d'absorption de monoamines
WO2005020976A2 (en) *	2003-08-27	2005-03-10	Eli Lilly And Company	Treatment of pervasive developmental disorders with norepinephrine reuptake inhibitors
CN1889940A (zh) *	2003-12-12	2007-01-03	伊莱利利公司	热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
WO2011027359A2 (en) *	2009-07-30	2011-03-10	Matrix Laboratories Ltd	Novel process for the preparation of 4-hydroxy atomoxetine
WO2012020418A1 (en)	2010-08-12	2012-02-16	Matrix Laboratories Ltd	Novel polymorphs of 4-hydroxy atomoxetine hydrochloride
DE102013022397A1 (de)	2013-12-19	2016-07-07	Metrax Gmbh	Vorrichtung zur Unterstützung eines Ersthelfers bei der Herzdruckmassage
GR1008819B (el)	2015-05-22	2016-08-01	Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων	Φαρμακευτικο σκευασμα που περιλαμβανει ατομοξετινη και μεθοδος παρασκευης αυτου
CN107935848B (zh) *	2017-11-21	2020-12-22	中国农业科学院兰州畜牧与兽药研究所	一种六茜素衍生物及其制备方法和应用
JP2022506113A (ja) *	2018-10-31	2022-01-17	アプニメッド，インコーポレイテッド（デラウェア）	睡眠時無呼吸を治療するための方法及び組成物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4194009A (en)	1974-01-10	1980-03-18	Eli Lilly And Company	Aryloxyphenylpropylamines for obtaining a psychotropic effect
US4314081A (en) *	1974-01-10	1982-02-02	Eli Lilly And Company	Arloxyphenylpropylamines
US4018895A (en)	1974-01-10	1977-04-19	Eli Lilly And Company	Aryloxyphenylpropylamines in treating depression
FR2432500A1 (fr) *	1978-02-24	1980-02-29	Roussel Uclaf	Nouveaux derives de la benzene propanamine et leurs sels, procede de preparation et application a titre de medicaments
US5112619A (en) *	1985-11-12	1992-05-12	Eli Lilly And Company	Orally administerable sustained release pharmaceutical formulation
US4956388A (en)	1986-12-22	1990-09-11	Eli Lilly And Company	3-aryloxy-3-substituted propanamines
CA1327795C (en) *	1987-08-14	1994-03-15	Jules Freedman	Antidepressants which are aryloxy inadanamines
CA2061665C (en) *	1991-02-25	2002-04-16	Mark Mortensen Foreman	Treatment of lower urinary tract disorders
TW514634B (en)	1997-10-14	2002-12-21	Lilly Co Eli	Process to make chiral compounds
WO2000058262A1 (en)	1999-03-29	2000-10-05	Eli Lilly And Company	Stereospecific method for preparing tomoxetine and intermediates thereof
WO2000061540A1 (en)	1999-04-09	2000-10-19	Eli Lilly And Company	Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
SK5422003A3 (en) *	2000-11-15	2003-12-02	Lilly Co Eli	Treatment of anxiety disorders
LU91038B1 (fr) *	2001-03-06	2003-09-11	Lilly Co Eli	Inhibiteur d'absorption de monoamines

2002
- 2002-02-20 LU LU91038A patent/LU91038B1/fr active
- 2002-02-20 TR TR2007/05146T patent/TR200705146T1/xx unknown
- 2002-02-20 AP APAP/P/2003/002855A patent/AP2003002855A0/en unknown
- 2002-02-20 CZ CZ20032380A patent/CZ20032380A3/cs unknown
- 2002-02-20 AU AU2002245385A patent/AU2002245385B2/en not_active Ceased
- 2002-02-20 US US10/468,553 patent/US20040082666A1/en not_active Abandoned
- 2002-02-20 EP EP02713538A patent/EP1379492B1/en not_active Revoked
- 2002-02-20 BR BR0207716-7A patent/BR0207716A/pt not_active IP Right Cessation
- 2002-02-20 DE DE60226715T patent/DE60226715D1/de not_active Revoked
- 2002-02-20 HR HR20030710A patent/HRP20030710A2/hr not_active Application Discontinuation
- 2002-02-20 NZ NZ527431A patent/NZ527431A/en unknown
- 2002-02-20 ES ES02713538T patent/ES2305221T3/es not_active Expired - Lifetime
- 2002-02-20 IL IL15777902A patent/IL157779A0/xx unknown
- 2002-02-20 AT AT0904202A patent/AT414238B/de not_active IP Right Cessation
- 2002-02-20 FI FI20031191A patent/FI20031191L/sv not_active IP Right Cessation
- 2002-02-20 EE EEP200300419A patent/EE200300419A/xx unknown
- 2002-02-20 CH CH01522/03A patent/CH695982A5/de not_active IP Right Cessation
- 2002-02-20 HU HU0303341A patent/HUP0303341A3/hu unknown
- 2002-02-20 WO PCT/US2002/003385 patent/WO2002070457A1/en not_active Ceased
- 2002-02-20 JP JP2002569778A patent/JP2004525912A/ja not_active Ceased
- 2002-02-20 GB GB0323169A patent/GB2389851B/en not_active Expired - Fee Related
- 2002-02-20 AT AT02713538T patent/ATE396170T1/de not_active IP Right Cessation
- 2002-02-20 SK SK1063-2003A patent/SK10632003A3/sk unknown
- 2002-02-20 CN CNB028060253A patent/CN1229331C/zh not_active Ceased
- 2002-02-20 CA CA002440161A patent/CA2440161A1/en not_active Abandoned
- 2002-02-20 KR KR10-2003-7011635A patent/KR20030092012A/ko not_active Ceased
- 2002-02-20 ES ES200350052A patent/ES2201942B2/es not_active Expired - Fee Related
- 2002-02-20 EA EA200300978A patent/EA005768B1/ru not_active IP Right Cessation
- 2002-02-20 OA OA1200300215A patent/OA12494A/en unknown
- 2002-02-20 PL PL02363840A patent/PL363840A1/xx not_active Application Discontinuation
2003
- 2003-08-11 LT LT2003075A patent/LT5143B/lt unknown
- 2003-09-02 EC EC2003004760A patent/ECSP034760A/es unknown
- 2003-09-03 SE SE0302361A patent/SE526598C2/sv not_active IP Right Cessation
- 2003-09-03 ZA ZA200306882A patent/ZA200306882B/en unknown
- 2003-09-04 DK DK200301267A patent/DK200301267A/da not_active Application Discontinuation
- 2003-09-04 NO NO20033921A patent/NO20033921L/no not_active Application Discontinuation
- 2003-09-10 LV LVP-03-100A patent/LV13119B/en unknown
2005
- 2005-05-09 US US11/125,348 patent/US7384983B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
WO2002070457A1 (en)	2002-09-12
SE526598C2 (sv)	2005-10-18
ATA90422002A (de)	2006-01-15
US20050209341A1 (en)	2005-09-22
NO20033921L (no)	2003-11-05
EA005768B1 (ru)	2005-06-30
PL363840A1 (pl)	2004-11-29
NZ527431A (en)	2005-05-27
ES2201942A1 (es)	2004-03-16
SE0302361L (sv)	2003-09-03
OA12494A (en)	2006-05-24
CA2440161A1 (en)	2002-09-12
GB2389851A (en)	2003-12-24
LT2003075A (en)	2004-03-25
IL157779A0 (en)	2004-03-28
NO20033921D0 (no)	2003-09-04
GB2389851B (en)	2005-05-25
AP2003002855A0 (en)	2003-08-20
TR200705146T1 (tr)	2008-02-21
LV13119B (en)	2004-06-20
CN1229331C (zh)	2005-11-30
EE200300419A (et)	2004-02-16
HUP0303341A3 (en)	2007-03-28
EA200300978A1 (ru)	2004-02-26
DK200301267A (da)	2003-11-06
AT414238B (de)	2006-10-15
SK10632003A3 (sk)	2004-06-08
DE60226715D1 (de)	2008-07-03
KR20030092012A (ko)	2003-12-03
ECSP034760A (es)	2003-10-28
FI20031191A7 (sv)	2003-08-25
CH695982A5 (de)	2006-11-15
EP1379492B1 (en)	2008-05-21
CN1494526A (zh)	2004-05-05
ES2201942B2 (es)	2004-12-16
AU2002245385B2 (en)	2007-01-18
GB0323169D0 (en)	2003-11-05
US7384983B2 (en)	2008-06-10
HRP20030710A2 (en)	2004-08-31
WO2002070457A8 (en)	2004-06-03
CZ20032380A3 (en)	2004-03-17
ZA200306882B (en)	2004-12-03
ES2305221T3 (es)	2008-11-01
EP1379492A1 (en)	2004-01-14
ATE396170T1 (de)	2008-06-15
JP2004525912A (ja)	2004-08-26
BR0207716A (pt)	2004-03-23
LT5143B (lt)	2004-06-25
US20040082666A1 (en)	2004-04-29
HUP0303341A2 (hu)	2004-01-28
LU91038B1 (fr)	2003-09-11
FI20031191L (sv)	2003-08-25

Publication	Publication Date	Title
CY1105386T1 (el)	2010-04-28	Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
TR200202194T2 (tr)	2003-01-21	Poliglütamik asit-kamptotesin birleşikleri ve hazırlama yöntemleri
ATE510534T1 (de)	2011-06-15	Naltrexonhydrochlorid-zusammensetzungen
MY138285A (en)	2009-05-29	Fab i inhibitors
DK1682530T3 (da)	2007-07-16	Pyrrolsubstituerede indoler som inhibitorer af PAI-1
IS6950A (is)	2003-09-12	Samsetning epóþílonhliðstæðna og efnameðferðarlyfja til meðhöndlunar frumufjölgunarsjúkdóma
CY1112487T1 (el)	2015-12-09	Βραχειας-δρασης ηρεμιστικοι υπνωτικοι παραγοντες για αναισθησια και καταστολη
IL163777A0 (en)	2005-12-18	Kinase inhibitors
GB0011358D0 (en)	2000-06-28	Novel use
CY1105980T1 (el)	2011-04-06	Βελτιωμενη διαδικασια παρασκευης υδροβρωμικου αλατος του αλφα-πολυμορφικου ελετριπτανιου
ATE375978T1 (de)	2007-11-15	Benzoylsulfonamide als antitumor-mittel
SE0301650D0 (sv)	2003-06-04	Novel compounds
SE0302361D0 (sv)	2003-09-03	Inhibering av upptagning av monoamin
DE60329326D1 (de)	2009-10-29	Tace inhibitoren
ATE315380T1 (de)	2006-02-15	Epothilon zusammensetzungen
BR0109512A (pt)	2002-12-17	Imidazopiridinas tricìclicas
DK1377574T3 (da)	2005-04-25	6-phenylbenzonaphtyridiner
NO20005548L (no)	2000-12-04	Mykobakterieinhibitorer
ATE343390T1 (de)	2006-11-15	Kalzilytische verbindungen
DK1144348T3 (da)	2006-06-12	LTA4-hydrolaseinhibitorer
ATE364037T1 (de)	2007-06-15	Tryptasehemmer
DE60102704D1 (de)	2004-05-13	Trioxepan verbindungen
CY1110139T1 (el)	2015-01-14	Γλυκοπεπτιδικα αντιβιοτικα
DOP2002000329A (es)	2002-08-30	Composicion solida
CY1115144T1 (el)	2016-12-14	Παραγωγα του uk-2a

Legal Events

Date	Code	Title	Description
2008-10-14	NUG	Patent has lapsed